Current Neuro-Oncology
Volume
23 Number 22
30 November 2021
Home > Publications > Current Neuro-Oncology > Volume 23, Year 2021 > Number 22, 30 November
*
Bauer
EK, Werner JM, Fink GR, Langen KJ, Galldiks N.
Case
Report: Detection
of
Symptomatic Treatment-Related Changes in a Patient With Anaplastic
Oligodendroglioma
Using FET PET.
Front
Oncol. 2021 Nov 16, 2021;11:735388∟.
doi: 10.3389/fonc.2021.735388∟.
PMID: 34868923∟.
Case report.
Fu
S, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D, Hong DS,
Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum
D.
A
phase I study of the WT2725 dosing emulsion in patients with
advanced malignancies.
Sci
Rep. 2021 Nov 16, 2021;11(1):22355∟.
doi: 10.1038/s41598-021-01707-3∟.
PMID: 34785698∟.
Interventional study.
Kirchner
MA, Holzgreve A, Brendel M, Orth M, Ruf VC, Steiger K, Pötter
D, Gold L, Unterrainer M, Mittlmeier LM, Barci E, Kälin RE,
Glass R, Lindner S, Kaiser L, Maas J, von Baumgarten L, Ilhan H,
Belka C, Notni J, Bartenstein P, Lauber K, Albert NL.
PSMA
PET Imaging in Glioblastoma: A Preclinical Evaluation
and
Theranostic Outlook.
Front
Oncol. 2021 Nov 17, 2021;11:774017∟.
doi: 10.3389/fonc.2021.774017∟.
PMID: 34869017∟.
Laboratory investigation.
Le
X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB,
Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR,
Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F,
Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E,
Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK.
Tepotinib
Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC:
Outcomes in Patient Subgroups from the VISION Study with Relevance
for Clinical Practice.
Clin
Cancer Res. 2021 Nov 17, 2022 Mar 15;28(6):1117-1126∟.
doi: 10.1158/1078-0432.CCR-21-2733∟.
PMID: 34789481∟.
Observational study.
Saran
F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris
F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M.
Afatinib
and radiotherapy, with or without temozolomide, in patients with
newly diagnosed glioblastoma: results of a phase I trial.
J
Neurooncol. 2021 Nov 17, 2021 Dec;155(3):307-317∟.
doi: 10.1007/s11060-021-03877-6∟.
PMID: 34787778∟.
Interventional study.
Akimoto
J, Fukami S, Ichikawa M, Nagai K, Kohno M.
Preliminary
Report: Rapid Intraoperative Detection of Residual Glioma Cell in
Resection Cavity Walls Using a Compact Fluorescence Microscope.
J
Clin Med. 2021 Nov 18, 2021;10(22):5375∟.
doi: 10.3390/jcm10225375∟.
PMID: 34830662∟.
Observational study.
Peach
MS, Burke AM, Jo J, Ju AW, Yang K.
GammaTile
Brachytherapy Combined
With
External Beam Radiation Therapy for the Treatment of a Partially
Resected
Secondary
Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching
External Beam
Dose Gradient to Brachytherapy Dose Fall-Off.
Cureus.
2021 Nov 18, 2021;13(11):e19717∟.
doi: 10.7759/cureus.19717∟.
PMID: 34934580∟.
Case report.
Pesce
A, Armocida D, Paglia F, Palmieri M, Frati A, D'Andrea G, Salvati
M, Santoro A.
IDH
Wild-type Glioblastoma Presenting with Seizure: Clinical
Specificity, and Oncologic and Surgical Outcomes.
J
Neurol Surg A Cent Eur Neurosurg. 2021 Nov 18∟.
doi: 10.1055/s-0041-1735515∟.
PMID: 34794192∟.
Observational study˰
Bunevicius
A, Pikis S, Kondziolka D, Patel DN, Bernstein K, Sulman EP, Lee
CC, Yang HC, Delabar V, Mathieu D, Cifarelli CP, Arsanious DE,
Dahshan BA, Weir JS, Speckter H, Mota A, Tripathi M, Kumar N,
Warnick RE, Peker S, Samanci Y, Barnett G, Hefnawi FE, Al Sideiri
G, Sheehan J.
Stereotactic
radiosurgery for IDH wild type glioblastoma: an international,
multicenter study.
J
Neurooncol. 2021 Nov 19, 2021;155(3):343-351∟.
doi: 10.1007/s11060-021-03883-8∟.
PMID: 34797526∟.
Observational study˰
Duchatel
RJ, Mannan A, Woldu AS, Hawtrey T, Hindley PA, Douglas AM, Jackson
ER, Findlay IJ, Germon ZP, Staudt D, Kearney PS, Smith ND, Hindley
KE, Cain JE, André N, La Madrid AM, Nixon B, De Iuliis GN,
Nazarian J, Irish K, Alvaro F, Eisenstat DD, Beck A, Vitanza NA,
Mueller S, Morris JC, Dun MD.
Preclinical
and clinical
evaluation of German-sourced ONC201 for the treatment of
H3K27M-mutant
diffuse
intrinsic pontine glioma.
Neurooncol
Adv. 2021 Nov 19, 2021;3(1):vdab169∟.
doi: 10.1093/noajnl/vdab169∟.
PMID: 34988452∟.
Observational
study.
Poon
MTC, Keni S, Vimalan V, Ip C, Smith C, Erridge S, Weir CJ, Brennan
PM.
Extent
of MGMT
promoter
methylation modifies the effect of temozolomide
on
overall survival in patients with glioblastoma: a regional cohort
study.
Neurooncol
Adv. 2021 Nov 19, 2021;3(1):vdab171∟.
doi: 10.1093/noajnl/vdab171∟.
PMID: 34988453∟.
Observational
study.
Lombardi
G, Spimpolo A, Berti S, Campi C, Anglani MG, Simeone R,
Evangelista L, Causin F, Zorzi G, Gorgoni G, Caccese M, Padovan M,
Zagonel V, Cecchin D.
PET/MR
in recurrent glioblastoma patients treated with regorafenib:
[18F]FET
and DWI-ADC for response assessment and survival prediction.
Br
J Radiol. 2021 Nov 23, 2022;95(1129):20211018∟.
doi: 10.1259/bjr.20211018∟.
PMID: 34762492∟.
Observational study.
Wang
Q, Niu W, Pan H.
Targeted
therapy with anlotinib for a H3K27M mutation
diffuse
midline glioma patient with PDGFR-α mutation: a case
report.
Acta
Neurochir (Wien). 2021 Nov 23, 2021:1–4∟.
doi: 10.1007/s00701-021-05061-1∟.
PMID: 34812950∟.
Case report.
Shieh
LT, Ho CH, Guo HR, Huang CC, Ho YC, Ho SY.
Epidemiologic
Features,
Survival,
and Prognostic Factors Among Patients With Different Histologic
Variants
of Glioblastoma: Analysis of a Nationwide Database.
Front
Neurol. 2021 Nov 24, 2021;12:659921∟.
doi: 10.3389/fneur.2021.659921∟.
PMID: 34899553∟.
Observational study.
Wen
PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von
Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A,
Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC,
Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran
P, Gasal E, Subbiah V.
Dabrafenib
plus trametinib in patients with BRAFV600E-mutant
low-grade and high-grade glioma (ROAR): a multicentre, open-label,
single-arm, phase 2, basket trial.
Lancet
Oncol. 2021 Nov 24, 2022;23(1):53-64∟.
doi: 10.1016/S1470-2045(21)00578-7∟.
PMID: 34838156∟.
Interventional study˰
Yan
P, Li JW, Mo LG, Huang QR.
A
nomogram combining inflammatory markers and
clinical
factors predicts survival in patients with diffuse
glioma.
Medicine
(Baltimore). 2021 Nov 24, 2021;100(47):e27972∟.
doi: 10.1097/MD.0000000000027972∟.
PMID: 34964788∟.
Observational study.
Wang
B, Zhang S, Wu X, Li Y, Yan Y, Liu L, Xiang J, Li D, Yan
T.
Multiple
Survival
Outcome Prediction of Glioblastoma Patients Based on
Multiparametric
MRI.
Front
Oncol. 2021 Nov 25, 2021;11:778627∟.
doi: 10.3389/fonc.2021.778627∟.
PMID: 34900728∟.
Observational study.
Chiocca
EA, Gelb AB, Chen CC, Rao G, Reardon DA, Wen PY, Bi WL, Peruzzi P,
Amidei C, Triggs D, Seften L, Park G, Grant J, Truman K, Buck JY,
Hadar N, Demars N, Miao J, Estupinan T, Loewy J, Chadha K,
Tringali J, Cooper L, Lukas RV.
Combined
immunotherapy with controlled Interleukin-12 gene therapy and
immune
checkpoint blockade in recurrent glioblastoma: an open-label,
multi-institutional phase 1 trial.
Neuro
Oncol. 2021 Nov 26, 2021:noab271∟.
doi: 10.1093/neuonc/noab271∟.
PMID: 34850166∟.
Interventional study.
*
Luan
XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou
J.
Extracranial
multiorgan metastasis from primary glioblastoma: A case
report.
World
J Clin Cases. 2021 Nov 26, 2021;9(33):10300-10307∟.
doi: 10.12998/wjcc.v9.i33.10300∟.
PMID: 34904103∟.
Case report.
Halatsch
ME, Dwucet A, Schmidt CJ, Mühlnickel J, Heiland T, Zeiler K,
Siegelin MD, Kast RE, Karpel-Massler G.
In
Vitro and Clinical Compassionate Use
Experiences
with the Drug-Repurposing Approach CUSP9v3 in
Glioblastoma.
Pharmaceuticals
(Basel). 2021 Nov 29, 2021;14(12):1241∟.
doi: 10.3390/ph14121241∟.
PMID: 34959641∟.
Expanded access study.
Di
Bella G, Borghetto V, Costanzo E.
A
retrospective observational study on
cases
of anaplastic
brain tumors treated with the Di Bella Method: A rationale
and
effectiveness.
Neuro
Endocrinol Lett. 2021
Nov 30, 2021;42(7):464-483∟.
PMID: 35490357∟.
Observational study.
Hwang
K, Kim J, Kang SG, Jung TY, Kim JH, Kim SH, Kang SH, Hong YK, Kim
TM, Kim
YJ, Choi BS, Chang JH, Kim CY.
Levetiracetam
as a sensitizer of concurrent
chemoradiotherapy
in newly diagnosed glioblastoma: An open-label phase 2
study.
Cancer
Med. 2021 Nov 30, 2021;11(2):371-379∟.
doi: 10.1002/cam4.4454∟.
PMID: 34845868∟.
Interventional
study.
Neth
BJ, Carabenciov ID, Ruff MW, Johnson DR.
Temporal
Trends in Glioblastoma Survival: Progress then
Plateau.
Neurologist.
2021 Nov 30, 2021;27(3):119-124∟.
doi: 10.1097/NRL.0000000000000393∟.
PMID: 34855660∟.
Observational study˰